Please assess the completion status of the following clinical trial:

Trial Title: A Study of TMC435 in Combination With Peginterferon Alfa-2A and Ribavirin for Hepatitis C Virus Genotype-1 Infected Patients Who Participated in a Control Group of a TMC435 Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who participated in the placebo arm of a TMC435 study who did not achieve undetectable HCV RNA levels at end of treatment or who relapsed within 1 year after end of treatment OR Patients who received short-term direct-acting antiviral therapy in a Tibotec-sponsored study.~* Liver disease stage documented by liver biopsy is required within 3 years prior to screening unless contraindicated.~Exclusion Criteria:~* Infection with human immunodeficiency virus.~* Liver disease not related to hepatitic C infection.~* Significant laboratory abnormalities or other active diseases.~* Pregnant or planning to become pregnant.~* Prematurely stopped medication in previous TMC435 study for non-compliance or for safety reasons.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- TMC435 (Type: EXPERIMENTAL): TMC435 Type=exact number unit=mg number=150 form=capsule route=oral use once daily for 12 weeks in addition to peginterferon alfa-2a peginterferon and ribavirin for 24 or 48 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).